Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...